C12N 2740/10052
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2740/10052 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 25 US grants and 54 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 54
- Assignees
- 39
- Inventors
- 97
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 4 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 4 |
| 2016 | 2 | 4 |
| 2017 | 0 | 3 |
| 2018 | 3 | 1 |
| 2019 | 0 | 3 |
| 2020 | 2 | 0 |
| 2021 | 2 | 4 |
| 2022 | 1 | 4 |
| 2023 | 0 | 7 |
| 2024 | 1 | 5 |
| 2025 | 8 | 5 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells2 Sep 2025US 12,404,525 B2President and Fellows of Harvard College
- Virus vector production15 Jul 2025US 12,359,217 B2Fondazione Telethon Ets
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells8 Jul 2025US 12,351,814 B2President and Fellows of Harvard College
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells8 Jul 2025US 12,351,815 B2President and Fellows of Harvard College
- Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of CD79A and CD79B10 Jun 2025US 12,325,728 B2Exuma Biotech Corp.
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof26 Feb 2026US 2026/0053924 A1
- Nucleic acid system to specifically reprogram b and t cells and uses thereof25 Dec 2025US 2025/0388932 A1Centre National De La Recherche Scientifique
- Virus vector production11 Dec 2025US 2025/0376696 A1Fondazione Telethon
Most cited
By later US patents
- Packaging cell22US 6,995,009 B1Chugai Seiyaku Kabushiki Kaisha · 2006
- Highly productive packaging lines20US 6,872,528 B2Universite Pierre et Marie Curie · 2005
- Methods and compositions for transducing lymphocytes and regulating the activity thereof3US 11,111,505 B2Exuma Biotech Corp. · 2021
- Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL3US 11,325,948 B2Exuma Biotech Corp. · 2022
- Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same3US 9,206,440 B2Roger Williams Hospital · 2015